• Publications
  • Influence
The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
TLDR
FM imposes a substantial humanistic burden on patients in the United States, and leads to substantial productivity loss, despite treatment, and this burden is higher among subjects with worse FM severity.
The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.
TLDR
This study examined the direct and indirect costs of fibromyalgia by severity level in routine clinical practice in the United States using a patient-centric approach and found differences across severity levels significantly differed.
Impact of fibromyalgia severity on health economic costs
TLDR
FM subjects were found to have substantial costs, over 75% of which were driven by indirect costs from lost productivity, which increased as FM severity increased, resulting in a more than 200% difference in cost between mild and severe FM.
Treatment patterns among physician specialties in the management of fibromyalgia: results of a cross-sectional study in the United States
TLDR
Pat characteristics were similar across specialties, except with regards to comorbidity burden, and treatment patterns among medications, diagnostics, and outpatient visits did not identify a dominant strategy for FM management.
Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales
TLDR
Evidence is provided of their content validity, supporting their use in FM studies and modifications to the MOS-Sleep may improve the psychometric properties and relevance to patients with FM.
Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia
TLDR
An FM diagnosis was associated with increased utilization and pain-related medication cost up to the first 6 months post-diagnosis followed by stabilization over 3 years post- Diagnosis, which suggests that further dissemination of treatment guidelines is needed.
Financial and clinical characteristics of fibromyalgia: a case-control comparison.
TLDR
FM cases had significantly higher utilization and costs compared with controls, and the use of pain-related medications accounted for the largest absolute differences between the 2 groups.
Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care
TLDR
Patients with FM prescribed pregabalin or duloxetine were characterized by a significant comorbidity and pain/adjuvant medication burden, and although healthcare costs increased in both groups, there were no statistically significant differences in direct healthcare costs between the two groups.
Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
TLDR
Comparisons between the three countries show differences in HRU, with significantly higher direct costs in the US compared with France and Germany, and indirect costs represented a significant proportion of the total costs, particularly in Europe.
Societal and individual burden of illness among fibromyalgia patients in France: Association between disease severity and OMERACT core domains
TLDR
As FM severity level worsened, patients had poorer overall health status and perceived their prescription medications to be less effective, and FM poses a substantial economic and human burden on patients and society.
...
...